Skip to main content


Coming Soon: KNOVA Joins Our Premier NIPT Screening Options

We are thrilled to announce the upcoming integration of KNOVA into our Non-invasive Prenatal Testing (NIPT) screening lineup. Renowned as a leader in NIPT technology in London and the UK, our expert team continually explores cutting-edge advancements in prenatal screening. 

KNOVA is set to become the leading choice for expectant families seeking the most advanced prenatal screening options.

Why Choose KNOVA? You probably need it…

KNOVA stands out as the most advanced extended NIPT option available globally. We are proud to include KNOVA as a part of our signature SMART test suite, reflecting our commitment to offering the best comprehensive prenatal care

  • Developed by Fulgent, a leading US genomic testing company, KNOVA is built on a robust foundational technology platform
  • Advanced Screening Capabilities: KNOVA extends the possibilities of prenatal screening with unparalleled accuracy
  • KNOVA offers the most comprehensive selection of chromosomal conditions and genetic syndromes currently available for prenatal screening
  • KNOVA provides a clinically valuable test, particularly for fetuses with increased nuchal translucency (NT) or other conditions, enhancing prenatal assessment and care
  • Rapid Results: Receive detailed insights swiftly, allowing for timely decisions
Fulgent KNOVA NIPT at London Pregnancy Clinic. Most advanced NIPT in London!

KNOVA NIPT is an integrated part of our SMART Test

KNOVA: The Premier Choice for NIPT

  • delivers superior performance in screening for Down’s (trisomy 21), Edwards (trisomy 18), and Patau (trisomy 13) syndromes

  • also checks for trisomy 22, trisomy 16, and trisomy 15, covering other clinically significant chromosomal conditions

  • screens for 12 microdeletions, more than any other NIPT currently available

  • looks for four sex chromosome aneuploidies, including Turner and Klinefelter syndromes

  • tests for 56 de novo mutations associated with a wide range of severe genetic disorders and rare diseases

  • KNOVA features a distinct selection of conditions screened, which does not overlap with those in the UNITY carrier screen (another advanced NIPT that we offer). This allows both tests to be used synergistically, enhancing diagnostic precision

  • SMART TEST – the most advanced SCAN & NIPT package in the world will include a primier KNOVA option soon


KNOVA is a new test, why can I trust it?

We trust KNOVA, developed by Fulgent Genetics, because of its cutting-edge technology and comprehensive genetic testing capabilities. Fulgent Genetics is renowned for its robust genomic testing platform, which combines advanced sequencing techniques with sophisticated data analysis. This allows KNOVA to offer a broader scope of prenatal screening, including detecting rare genetic disorders and a wide array of chromosomal abnormalities.

As with any other NIPT screening, KNOVA is not diagnostic; it is a critical first step in identifying high-risk pregnancies.

Why we have chosen KNOVA?

Unrivalled Breadth in Prenatal Screening
KNOVA stands out as an extended NIPT that screens the widest panel of chromosomal and genetic conditions available.

Understanding NIPT Options: Basic vs Extended
Typically, NIPTs come in two forms: basic and extended. Basic NIPTs, such as the Harmony Test or PrenatalSafe 3UK, primarily detect common chromosomal syndromes like Down, Edwards, and Patau syndromes. These tests may also determine the baby’s sex. In contrast, extended NIPTs, including the Panorama Test, PrenatalSafe Complete Plus, UNITY, and KNOVA, cover a broader spectrum of fetal genetic conditions. These can identify rare syndromes and even assess the fetal blood group.

While many providers offer both basic and extended options, the coverage varies significantly across different tests. This variation often stems from the diverse genetic technologies employed by biogenetic companies, potentially leading to confusion among parents making critical prenatal decisions.

Why Choose KNOVA?
To simplify choices for expectant parents, Fulgent has developed KNOVA as a single, all-encompassing NIPT option. It aims to cover as many genetic conditions as possible, ensuring broad and effective prenatal screening.

The SMART Test: A Synergy of Advanced Technology and Extensive Screening
London Pregnancy Clinic, a leader in expert ultrasound and NIPT, is proud to present the SMART Test. This advanced offering combines the latest ultrasound technology with the most sophisticated NIPTs available, including soon-to-be-integrated KNOVA. 

Choose the SMART Test at London Pregnancy Clinic for an in-depth understanding of your baby’s health and genetic predispositions. Contact us today to learn more about how the SMART Test, featuring KNOVA, can provide the insights you need for peace of mind during your pregnancy journey.

Fast NIPT options available at London Pregnancy Clinic

At London Pregnancy Clinic, KNOVA is not the fastest NIPT available due to the logistics involved. The test is conducted in the US, and some time is lost while shipping samples. If your primary concern is screening for Down syndrome only, our UK-based Prenatalsafe test, with a turnaround time of 2-5 days, might be a more suitable option. However, Fulgent’s KNOVA offers unbeatable performance with an extended NIPT panel for those requiring a more comprehensive analysis. Excluding the shipping time (which can be variable), no other company can match the breadth and depth of testing Fulgent provides within a 7-10 day timeframe.

How is the test performed?

Initially, our Fetal Medicine Doctor or Advanced Sonographer will perform a detailed anatomical assessment of your baby. They focus on identifying any structural anomalies and gathering measurements for the NIPT.

After confirming the baby’s normal structural assessment, they will offer a consultation about the NIPT. During this consultation, you can ask questions and understand every aspect of the test. Our team will help you choose the NIPT best suited to your needs.

Then, our friendly phlebotomist will take a small blood sample from your arm — much like routine blood tests you might have elsewhere.

Once we’ve collected your blood sample, our dedicated staff will promptly process it and send it off to the laboratory. After your appointment, the only thing left is to wait for a call from our team with your results.

Why do I need to have an ultrasound scan with NIPT?

Ultrasound is crucial in the comprehensive assessment of fetal health. To ensure precise results, the laboratory requires confirmation of viability and gestational age from the clinic submitting each NIPT.

While NIPT is an excellent screening tool for chromosomal anomalies and genetic syndromes, it’s vital to recognise its limitations in detecting structural anomalies, such as heart or brain defects. These anomalies, often more critical and common than Down’s Syndrome, are not detectable through NIPT.

At London Pregnancy Clinic, we excel in the early detection of fetal anomalies, with a particular focus on the fetal heart and brain. Our expertise enables us to identify some of the most serious fetal anomalies as early as the 10th week of pregnancy. This commitment to early detection and specialised care distinguishes us in securing the best possible outcomes for both you and your baby’s health.

Visit our Scans Page to find out which scan you will be having along with NIPT. Generally, we believe that our 10 Weeks Scan is the best option.

Can KNOVA NIPT screen for hereditary diseases?

Can KNOVA NIPT screen for hereditary diseases? No. KNOVA primarily screens for de novo diseases like Down syndrome, which typically arise from genetic errors during conception in genetically healthy parents. However, Fulgent Genetics, the provider of KNOVA, is renowned for its carrier screening tests for hereditary disorders. BEACON’s Expanded Panels, developed by Fulgent, can screen for over 700 recessive and X-linked conditions, addressing both common and rare risks across all ethnicities.

At London Pregnancy Clinic, we are soon introducing paternal carrier screening as an addition to our extended NIPT panels. Don’t hesitate to contact us with any enquiries.

Can we do KNOVA for twins or triplets?

Unfortunately, due to the specific advanced technology that Fulgent employs, twins and triplets pregnancies are not eligible for KNOVA screening.

Can we do KNOVA for egg donor pregnancies?

Unfortunately, due to the specific advanced technology that Fulgent uses, IVF pregnancies using an egg donor are not eligible for KNOVA screening

What is The SMART Test?

Coming soon! SMART Test with Fulgent KNOVA NIPT

The SMART Test (NIPT) stands out as the epitome of advanced non-invasive prenatal testing packages globally. It integrates cutting-edge ultrasound technology alongside the most sophisticated NIPT available. This comprehensive package encompasses screening not only for Down syndrome but also for approximately 100 distinct severe rare genetic diseases.

This all-encompassing test comprises two expert fetal scans, and PrenatalSafe Complete Plus, or KNOVA NIPT

Developed by the London Pregnancy Clinic, a leader in expert ultrasound and NIPT, the SMART Test offers the ultimate solution for parents seeking the most comprehensive assessment of their baby’s health and genetic profile. By combining state-of-the-art ultrasound techniques with advanced genetic screening technologies, the SMART Test is the pinnacle of options for parents who wish to gain the utmost knowledge about their unborn babies.

We recommend performing the SMART Test at 10 weeks. Press here for more information about our SMART Test package.

Our NIPT + Early Anomaly Scan always incorporates chromosomal anomaly and structural screening from as early as 10 weeks



Prenatal SAFE

Panorama AI

Panorama AI
Most advanced NIPT

Smart Test® with KNOVA

Smart TEST®
As early as…
  • 10 weeks

  • 9 weeks

  • 10 weeks

Turnaround (Working Days)
  • 2-4

  • 5-7

  • 10-14

Lab Location
  • UK

  • US

  • US

No Call Results
  • 0.5%

  • 1%

  • 0.5%

Redraw Rate
  • 2%

  • 3%

  • 2%

Down, Edwards, & Patau Syndrome
Di George Syndrome (22q del)
Turner Syndrome (45X)
Sex chromosomes aneuploidies
Additional chromosomes
Chromosomal deletions & duplications
  • 5 (+£200)

  • 12

Inherited monogenic disorders 
  • add Beacon

Important Genetic syndromes
Comprehensive anomaly Ultrasound screening
Fetal echocardiography
Fetal sex reveal (optional)
Scan & NIPT price
  • £540

  • £590

  • coming soon **

  • £790 for Microdeletions

  • **introduction offer

Frequently Asked Questions

Your questions answered

What is NIPT or NIPS?

Non-Invasive Prenatal Testing (NIPT), also known as Non-Invasive Prenatal Screening (NIPS), serves to evaluate the likelihood of conditions such as Down’s syndrome or other chromosomal and single gene disorders in unborn babies. NIPT analyses small DNA fragments from the baby’s placenta, known as ‘cell-free DNA’ or ‘cfDNA’, which circulate in the bloodstream of pregnant mothers. This placental cfDNA generally mirrors the baby’s DNA, allowing early identification of certain chromosomal anomalies without any risk to the baby.

It’s crucial to understand that NIPT is a screening test, meaning it does not confirm whether the baby has Down’s syndrome or other chromosomal conditions. Should the results show a high chance, further invasive testing is required for a definitive diagnosis. However, bear in mind that such invasive testing carries a slight risk of miscarriage.

Understanding the statistical aspects of KNOVA NIPT

According to data from Fulgent, in a study involving over 1000 high-risk pregnancies, KNOVA achieved a 98.5% sensitivity rate and a 99.3% specificity rate. This performance compares favorably to standard diagnostic tests, both prenatal invasive and postnatal, for the multiple conditions screened—not just Down’s syndrome.

We wrote a special blog post about understanding the statistics of the NIPT test. If you would like to find out more, click here.

Why KNOVA has no basic NIPT option?

We cannot specify precisely, as it remains a company commercial secret. However, we believe that Fulgent, a highly renowned genomic company with the capability to examine over 18,000 human genes, is confident that integrating their microdeletions and monogenic screening platforms will significantly boost NIPT’s performance. Fulgent possesses advanced genetic tools essential for developing and implementing this test. Their preliminary data indicate that including targeted monogenic conditions alongside chromosomal abnormalities (aneuploidies and microdeletions) resulted in a 60.7% increase in the detection rate.

Which aneuploidies (autosomal trisomies) does KNOVA NIPT cover?

KNOVA screens for 5 types of chromosomal syndromes associated with severe health/mental conditions or possible fetal demise:

  1. Trisomy 21 – Down syndrome
  2. Trisomy 18 – Edwards syndrome
  3. Trisomy 13 – Patau syndrome
  4. Trisomy 15
  5. Trisomy 16
  6. Trisomy 22
Which microdeletions does KNOVA NIPT cover?

KNOVA screens for 12 chromosomal microdeletions associated with severe health/mental conditions:

  1. 1p36 del-  1p36 deletion syndrome
  2. 2q33 del – 2q33.1 deletion syndrome
  3. 4p16 del – Wolf-Hirschhorn syndrome
  4. 5p15 del – Cri-du-Chat syndrome
  5. 8q23q24 del – Langer-Giedion syndrome
  6. 9p del – 9p deletion syndrome
  7. 11q23q25 del – Jacobsen syndrome
  8. 15q11.2-q13 del – Prader-Willi syndrome / Angelman syndrome
  9. 17p11.2 del – Smith-Magenis syndrome
  10. 18p del – 18p deletion syndrome
  11. 18q22q23 del – 18q deletion syndrome
  12. 22q11.2 del – 22q11.2 deletion syndrome (DiGeorge syndrome)
Which monogenic syndromes (single-gene disorders) does KNOVA NIPT cover?

KNOVA screens for 56 genes associated with 30+ monogenic conditions. Among them are:

  • Noonan syndrome
  • Noonan spectrum disorders (RASOpathies)
  • Skeletal dysplasias
  • Craniosynostoses
  • CHARGE syndrome
  • Cornella de Lange syndrome
  • Tuberous sclerosis complex
  • Sotos syndrome 
  • and many others
Why 10 weeks is the best time to perform KNOVA NIPT?

We strongly recommend undertaking the NIPT alongside our comprehensive early anomaly scan, the 10 Weeks Scan, as soon as possible—ideally at 10 weeks into your pregnancy. Early detection of chromosomal or structural anomalies offers greater flexibility in managing these conditions throughout your pregnancy. Should there be a sample failure, there is sufficient time for a redraw without any delays.

If you are unsure about the exact stage of your pregnancy, we recommend our Viability Scan at around 7-8 weeks. This scan determines the age of your pregnancy, enabling us to schedule your NIPT at the earliest opportunity.

If you decide against the Viability Scan, please wait a few days after reaching the 10-week mark to avoid the need for repeat blood collection appointments. Coming too early may also mean missing out on the full benefits of the 10 Weeks Scan if your baby is too young for a thorough early anomaly assessment.

While NIPT can technically be conducted from 10 to 40 weeks, we strongly advise opting for the test in the first trimester. Management options for pregnancy become more limited as the second trimester progresses.

Who is NOT eligible for KNOVA Test?

The KNOVA Prenatal Cell-Free DNA Screening has not been validated for use in pregnancies involving:

  • a history of or active malignancy
  • IVF pregnancies using an egg donor
  • a pregnancy with twins, triplets, quadruplets or higher-order
  • vanishing twin syndrome
  • a history of bone marrow or organ transplants
  • mosaicism for the parents
  • maternal aneuploidy (chromosomal abnormality), microdeletion or single-gene disorder

How are the outcomes of the NIPT test shared with you?

After your scan, our medical experts will provide you with a detailed scan report in both printed form and as a PDF, securely delivered through our cloud platform, Tricefy.

Once we receive the NIPT test results from the laboratory, our clinicians will review and authorize them. Following this, a member of our friendly clinical team will contact you by phone to discuss the implications of your results. We will then send you an electronic version of the results via Tricefy for your reference.

What if my NIPT results show high chance for a chromosomal or genetic disease?

KNOVA is not a diagnostic tool and should not be used as the sole basis for making decisions about your pregnancy. It is designed to identify if your pregnancy has a higher-than-average risk of a severe disorder, allowing you the option to consider further diagnostic testing if needed. As KNOVA is a non-invasive test, it presents a relatively low risk and serves as an excellent initial screening option.

Should the NIPT indicate a high chance of Down syndrome or another condition, our doctor will contact you to explain the recommended next steps. Typically, high-risk results require confirmation through diagnostic tests, such as CVS (Chorionic Villus Sampling) or amniocentesis.

Our medical and administrative teams are committed to supporting you through challenging times. They will do everything possible to facilitate smooth and prompt arrangements for further genetic counselling and diagnostic procedures, should they be necessary.

I have pregnancy with vanishing twin, can I do KNOVA NIPT?

No, KNOVA NIPT is not suitable in cases of vanishing twin syndrome.

Vanishing twin syndrome occurs in twin pregnancies when one embryo or fetus does not develop or perishes early in pregnancy. This condition complicates NIPT interpretation due to DNA contamination from the non-developing twin. Similarly, Panorama NIPT is unsuitable under these circumstances.

However, we offer a specific solution for pregnancies impacted by this rare condition: the PrenatalSafe Test, designed to be effective in cases of vanishing twin syndrome. Please contact us to learn more.

Does KNOVA have a validation study?

Validation study for KNOVA Prenatal Cell-Free
DNA Screening (NIPT/NIPS) was published in Nature.

Zhang J, et al. Prospective prenatal cell-free DNA screening for genetic conditions of heterogenous etiologies. Nat Med. 2024 Feb;30(2):470-479.


Prenatal cell-free DNA (cfDNA) screening uses extracellular fetal DNA circulating in the peripheral blood of pregnant women to detect prevalent fetal chromosomal anomalies. However, numerous severe conditions with underlying single-gene defects are not included in current prenatal cfDNA screening. In this prospective, multicenter and observational study, pregnant women at elevated risk for fetal genetic conditions were enrolled for a cfDNA screening test based on coordinative allele-aware target enrichment sequencing. This test encompasses the following three of the most frequent pathogenic genetic variations: aneuploidies, microdeletions and monogenic variants. The cfDNA screening results were compared to invasive prenatal or postnatal diagnostic test results for 1,090 qualified participants.

The comprehensive cfDNA screening detected a genetic alteration in 135 pregnancies with 98.5% sensitivity and 99.3% specificity relative to standard diagnostics. Of 876 fetuses with suspected structural anomalies on ultrasound examination, comprehensive cfDNA screening identified 55 (56.1%) aneuploidies, 6 (6.1%) microdeletions and 37 (37.8%) single-gene pathogenic variants. The inclusion of targeted monogenic conditions alongside chromosomal aberrations led to a 60.7% increase (from 61 to 98) in the detection rate. Overall, these data provide preliminary evidence that a comprehensive cfDNA screening test can accurately identify fetal pathogenic variants at both the chromosome and single-gene levels in high-risk pregnancies through a noninvasive approach, which has the potential to improve prenatal evaluation of fetal risks for severe genetic conditions arising from heterogenous molecular etiologies.

Is KNOVA clinically beneficial in the cases of increased nuchal translucency (NT)?

KNOVA is not a diagnostic tool and should not solely guide decisions about your pregnancy. It is designed to detect if there is a higher-than-average risk of a severe disorder, offering you the possibility of further diagnostic testing. While the data from invasive tests like CVS or amniocentesis are generally more conclusive, these tests often do not assess for monogenic disorders associated with increased nuchal translucency (NT), such as Noonan syndrome, Kabuki syndrome, and Thanatophoric dysplasia. An exome analysis would be required, and the NHS has stringent criteria for such tests, which generally do not apply merely for increased NT. In our view, KNOVA is the NIPT of choice in cases of increased NT, providing a valuable screening option when detailed diagnostic testing may not be feasible.

Please contact us if you would like more information regarding NIPT options for fetuses with increased NT.

Do you want to know more about your options of NIPT?

Please do not fill this field!
Please do not fill this field!